...will also assume rights to BioSante's existing license agreement for GVAX melanoma vaccine with the John P. Hussman Foundation...

...for up to $39 million in milestones and 15-33% of sublicense revenues, plus royalties. The Hussman Foundation...
...to treat stage IIb-IV melanoma (see BioCentury, Jan. 31). BioSante Pharmaceuticals Inc. (NASDAQ:BPAX), Lincolnshire, Ill. John P. Hussman Foundation...